At present, there is more than one dual layered stent in the market offering additional protection in carotid PCI. Therefore we saw fit to look at these devices to compare class benefits and find any specific differences. This study assessed the safety and efficacy of two dual layered mesh covered stents especially designed for carotid<a href="https://solaci.org/en/2020/11/05/dual-layered-for-dual-protection-in-carotid-pci/" title="Read more" >...</a>
Watch again the “8° ProEducar Educational Meeting – Learning with the Experts”, on Extracardiac Interventions on our Youtube channel. What things will I learn if I watch this video? 04:03 | Pulmonary angioplasty in chronic thromboembolic disease. When and how to perform endovascular treatment? – Fabio Solano Souza (BRA) 37:54 | Venous Intervention I: Deep<a href="https://solaci.org/en/2020/10/30/8-proeducar-educational-meeting-extracardiac-intervention/" title="Read more" >...</a>
Pretreating non-ST elevation acute myocardial infarction (NSTEMI) patients with P2Y12 receptor inhibitors is not associated with improved clinical outcomes as it is to increased bleeding. NSTEMI patients are often treated with platelet antiaggregants in the daily clinical practice despite the lack of evidence for its benefits. This Swedish registry prospectively included 64857 patients undergoing NSTEMI<a href="https://solaci.org/en/2020/10/28/is-loading-nstemi-with-dapt-convenient/" title="Read more" >...</a>
The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3 years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv. At 3 years, target-vessel failure remained lower in patients whose angioplasty was guided by<a href="https://solaci.org/en/2020/10/22/tct-2020-our-next-goal-should-be-using-ivus-guidance-in-every-angioplasty/" title="Read more" >...</a>
Ticagrelor monotherapy after 3 months of dual antiplatelet therapy in patients who experienced ST-segment elevation infarction significantly reduces major bleeding without increasing ischemic risk. This pre-specified analysis of the TICO study shows that ticagrelor monotherapy is safe even in patients with higher ischemic risk. Interrupting aspirin use after 3 months of dual antiplatelet therapy and continuing treatment<a href="https://solaci.org/en/2020/10/22/tct-2020-ticagrelor-monotherapy-after-st-segment-elevation-infarction/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) results durable at 5 years to treat failed surgical bioprosthetic valves and at one year to treat valves percutaneously. Regardless the type of the failed valve, the solution is TAVR. The 5 year follow up of the PARTNER 2 valve-in-valve (ViV) showed that TAVR as treatment for failed surgical bioprosthetic<a href="https://solaci.org/en/2020/10/21/tct-2020-tavr-appears-to-be-the-solution-for-all-dysfunctional-biological-valves/" title="Read more" >...</a>
This is the largest and newest study to compare drug eluting stents with durable polymers vs. biodegradable or bioresorbable polymers. As is usually the case, the theory clashes with reality. The study has shown that the polymer does not seem to play an important role in the performance of drug eluting stents, or at least<a href="https://solaci.org/en/2020/10/21/tct-2020-the-myth-of-biodegradable-polymers-seems-to-have-come-to-an-end/" title="Read more" >...</a>
Patients who undergo coronary angioplasty after acute coronary syndrome could de-escalate dual antiplatelet therapy with prasugrel to maintain the protection against ischemic events while lowering their hemorrhagic risk. The HOST-REDUCE-POLYTECH-ACS study (recently published in The Lancet) included 2338 patients who underwent coronary angioplasty in a setting of acute coronary syndrome. Patients were randomized to a year-long<a href="https://solaci.org/en/2020/10/21/how-to-de-escalate-prasugrel-after-acute-coronary-syndrome/" title="Read more" >...</a>
Diabetes has an impact on the relative effect of ticagrelor and prasugrel in patients undergoing acute coronary syndrome (ACS) according to a recent analysis of the ISAR-REACT 5 published in JACC Intv. Similarly to the main study outcomes, this sub-analysis of the ISAR-REACT 5 has shown that the combined end point of death, MI or<a href="https://solaci.org/en/2020/10/16/diabetes-could-decide-between-ticagrelor-and-prasugrel/" title="Read more" >...</a>
Patients with a bigger number of complex anatomical characteristics that increase PCI complexity have worse results at one-year followup. These data come from a large multicenter study (e-Ultimaster) recently published in EuroIntervention. The more complex the characteristics, the greater the increase in events. It is important to see past the obvious anatomical challenges (bifurcations, calcification,<a href="https://solaci.org/en/2020/10/14/complex-pci-complex-characteristics-impact-results/" title="Read more" >...</a>